Molecular diagnosis & therapy · 2026
Diagnostic Performance of the ASCL1/ZNF582 Methylation Test for Detection of High-Grade Vulvar Intraepithelial Neoplasia and Vulvar Cancer.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
de Vries Dominique C, Runello Flavia, Duin Sylvia, Berkhof Johannes, Steenbergen Renske D M, Bleeker Maaike C G
Аннотация
INTRODUCTION: High-grade vulvar intraepithelial neoplasia (VIN), the precursor lesion to vulvar cancer, comprises human papillomavirus (HPV)-associated high-grade squamous intraepithelial lesion (HSIL) and HPV-independent VIN (HPVi-VIN), differing in pathogenesis and cancer risk. HSIL typically develops from low-grade squamous intraepithelial lesion (LSIL), and HPVi-VIN from lichen sclerosus (LS). The PreCursor-M AnoGYN Methylation test, targeting ASCL1/ZNF582, may improve diagnostic accuracy and risk stratification in high-grade VIN patients. This study assessed its diagnostic performance to detect high-grade VIN and cancer.
METHODS: ASCL1/ZNF582 methylation was analyzed in 170 vulvar formalin-fixed paraffin-embedded (FFPE) tissue samples from healthy controls, LS, LSIL, HSIL, HPVi-VIN and vulvar cancer patients by quantitative methylation-specific polymerase chain reaction (qMSP). Logistic regression analysis was used to evaluate its diagnostic performance and compare it to the previously established ZNF582/SST/miR124-2 marker panel.
RESULTS: Methylation levels increased with disease severity, from low in controls, LS and LSIL to high in HSIL, HPVi-VIN and vulvar cancer. The ASCL1/ZNF582 marker panel detected 92% and 84% of HSIL at 70% and 80% specificity, respectively, and 96% of HPVi-VIN and 100% of vulvar cancer at both specificities. Both marker panels (ASCL1/ZNF582 and ZNF582/SST/miR124-2) showed comparable excellent diagnostic performance for high-grade VIN detection, with an area under the curve (AUC) of 0.93 (95% confidence interval [CI] 0.88-0.98) and AUC 0.91 (95% CI 0.86-0.97), respectively.
CONCLUSIONS: In conclusion, the ASCL1/ZNF582 methylation assay accurately detects high-grade VIN and vulvar cancer, while minimizing the detection of benign and low-grade lesions, indicating its clinical value.
METHODS: ASCL1/ZNF582 methylation was analyzed in 170 vulvar formalin-fixed paraffin-embedded (FFPE) tissue samples from healthy controls, LS, LSIL, HSIL, HPVi-VIN and vulvar cancer patients by quantitative methylation-specific polymerase chain reaction (qMSP). Logistic regression analysis was used to evaluate its diagnostic performance and compare it to the previously established ZNF582/SST/miR124-2 marker panel.
RESULTS: Methylation levels increased with disease severity, from low in controls, LS and LSIL to high in HSIL, HPVi-VIN and vulvar cancer. The ASCL1/ZNF582 marker panel detected 92% and 84% of HSIL at 70% and 80% specificity, respectively, and 96% of HPVi-VIN and 100% of vulvar cancer at both specificities. Both marker panels (ASCL1/ZNF582 and ZNF582/SST/miR124-2) showed comparable excellent diagnostic performance for high-grade VIN detection, with an area under the curve (AUC) of 0.93 (95% confidence interval [CI] 0.88-0.98) and AUC 0.91 (95% CI 0.86-0.97), respectively.
CONCLUSIONS: In conclusion, the ASCL1/ZNF582 methylation assay accurately detects high-grade VIN and vulvar cancer, while minimizing the detection of benign and low-grade lesions, indicating its clinical value.